Introduction {#s1}
============

Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly and the leading cause of dementia in humans ([@B11]; [@B31]). It is suggested that genetic risk factors could cause AD ([@B48]). In recent years, kinds of methods have been used to detect the underlying AD genetic factors. For example, candidate gene studies have identified mutations in *APP*, *PSEN1*, and *PSEN2* to be associated with autosomal dominant AD ([@B48]). *APOE* has been reported to be associated with both early- and late-onset AD ([@B48]). Large-scale genome-wide association studies (GWASs) have identified several novel genetic risk loci in European population, and candidate gene studies have replicated these findings in other populations ([@B22]; [@B35]; [@B33]; [@B34]; [@B24]; [@B27]; [@B32]; [@B3]; [@B18]; [@B43]; [@B54]; [@B2]; [@B19]; [@B20]; [@B28]; [@B40]; [@B45]; [@B51]). Whole-genome sequencing has highlighted the role of *TREM2* in AD ([@B12]; [@B53]; [@B46]). However, these AD susceptibility loci could only explain 28.57% AD genetic risk ([@B5]). Large proportion of AD heritability remains unclear.

It is reported that the cellular trafficking and recycling machineries are associated with AD risk ([@B1]). [@B1] found that the coat protein complex I (COPI)--dependent trafficking *in vivo* could significantly reduce amyloid plaques in the cortex and hippocampus of neurological in the AD mouse models. [@B1] further analyzed the human genetic association study data and identified 12 single-nucleotide polymorphisms (SNPs) in COPI genes, which are significantly associated with increased AD risk including *COPA* (rs7531886 and rs12033011), *COPB1* (rs72868007), *COPD/IFT46* (rs73022058 and rs3132828), *COPD/PHLDB1* (rs498872), *COPZ1* (rs34280607 and rs61614746), *COPZ2* (rs757352, rs9898218, rs7216504), and *COPZ2/NFE2L1* (rs11650615).

In their study, Bettayeb et al. [@B1] selected six independent study cohorts including two family-based studies and four case-control association studies and further performed a meta-analysis using a total of 6,795 samples (4,018 AD cases and 2,777 controls). Until now, large-scale GWASs have been performed ([@B7]; [@B14]; [@B8]; [@B15]; [@B10]). Hence, we used a large-scale AD GWAS dataset to investigate the association of these 12 genetic variants and the COPI genes and AD risk by a single SNP test and a gene-based test ([@B15]). Meanwhile, considering the unknown function of the significant SNP, we conducted an expression quantitative trait loci (eQTLs) analysis.

Materials and Methods {#s2}
=====================

AD GWAS Dataset {#s2_1}
---------------

We selected the AD GWAS dataset from the International Genomics of Alzheimer's Project (IGAP) ([@B15]). International Genomics of Alzheimer's Project is a large two-stage study based on GWAS on individuals of European ancestry. In stage 1, IGAP used genotyped and imputed data on 7,055,881 SNPs for meta-analysis of four previously published GWAS datasets consisting of 17,008 Alzheimer's disease cases and 37,154 controls (European Alzheimer's disease Initiative, Alzheimer Disease Genetics Consortium, Cohorts for Heart and Aging Research in Genomic Epidemiology consortium, Genetic and Environmental Risk in AD consortium) ([@B15]). All patients with AD satisfied the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria or the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* guidelines ([@B15]). Previous studies have provided more detailed information about IGAP dataset ([@B11]; [@B26]; [@B39]).

SNP-Based Test {#s2_2}
--------------

Here, we investigated the association between these 12 variants and AD susceptibility using the summary association results from the above study ([@B15]). If one of these 12 variants is not available in the AD GWAS dataset, we used HaploReg (version 4) to identify the proxy SNPs based on the linkage disequilibrium (LD) information in 1000 Genomes Project ([@B50]).

Gene-Based Test {#s2_3}
---------------

We performed a gene-based test of this large-scale AD GWAS dataset using a common method PLINK (SET SCREEN TEST) ([@B41]). PLINK is a meta-analysis using all the SNPs in the corresponding genes ([@B41]). The method uses an approximate Fisher's test to combine *P* values across all the SNPs in genes and adjusts for LD ([@B41]). Meanwhile, we performed a gene-based test of this large-scale AD GWAS dataset using VEGAS ([@B25]). VEGAS software incorporates information from all SNPs within a gene and adjusts the gene sizes, SNP density, and the LD between SNPs ([@B25]). VEGAS assigns SNPs to 17,787 autosomal genes according to the positions of SNPs and genes (± 50 kb from the 5′ and 3′ UTR) ([@B25]). Previous studies have provided more detailed information about the PLINK and VEGAS methods ([@B21]; [@B36]; [@B17]; [@B16]).

eQTLs Analysis {#s2_4}
--------------

We selected the eQTLs dataset from the Brain eQTL Almanac (Braineac), which is a web-based resource to access the UK Brain Expression Consortium dataset ([@B42]). This resource included 134 neuropathologically normal individuals of European descent in 10 brain tissues ([@B42]). For each sample, we got his/her COPI gene expression data and the genotype data for 12 SNPs ([@B42]). We then evaluated their association with nearby gene expression using a linear regression analysis under an additive model. In addition to normal human brain tissues, we further evaluated whether these genetic variants could regulate the expression of nearby genes in neurodegenerative disease tissues. We selected two eQTLs datasets from 197 AD cerebellar samples and 202 AD temporal cortex samples ([@B55]). The significance level is *P* \< 0.05. Recent studies have provided more detailed information about the eQTLs using Braineac ([@B9]; [@B26]; [@B37]; [@B23]; [@B29]; [@B38]; [@B52]). In addition, we conducted an eQTLs analysis in whole blood using the large-scale dataset from the eQTLGen Consortium ([@B47]). The consortium incorporates 37 datasets, with a total of 31,684 individuals ([@B47]).

Results {#s3}
=======

SNP-Based Test {#s3_1}
--------------

Using SNP-based test, we found that 10 of the 12 SNPs were included in this GWAS dataset except rs7531886 and rs34280607 variants. We further applied HaploReg (version 4) to identify their proxy SNPs based on the LD information from the 1000 Genomes Project (EUR) ([@B50]). We selected two best tagged SNPs including rs2298104 LD with rs7531886 (*r* ^2^ = 0.84 and *D*′ = 0.99), as well as rs34192202 LD with rs34280607 (*r* ^2^ = 0.69 and *D*′ = 0.91). The results indicated that among these 12 SNPs only rs9898218 showed significant association with AD risk with *P* = 0.017, as described in [**Table 1**](#T1){ref-type="table"}.

###### 

12 SNPs in COPI genes and Alzheimer's disease susceptibility.

  SNP             Gene           Chr:pos (hg19)   EA   NEA   β        SE      *P* value
  --------------- -------------- ---------------- ---- ----- -------- ------- -----------
  rs7531886^a^    COPA           1:160260233      T    C     −0.025   0.016   0.113
  rs12033011      COPA           1:160296055      A    G     0.005    0.019   0.806
  rs72868007      COPB1          11:14479553      A    C     0.040    0.044   0.364
  rs73022058      COPD/IFT46     11:118423672     T    C     −0.025   0.024   0.302
  rs3132828       COPD/IFT46     11:118431003     A    G     0.029    0.021   0.164
  rs498872        COPD/PHLDB1    11:118477367     A    G     0.011    0.017   0.498
  rs34280607^b^   COPZ1          12:54684768      A    G     0.045    0.044   0.305
  rs61614746      COPZ1          12:54740214      A    G     −0.019   0.026   0.475
  rs757352        COPZ2          17:46097153      A    G     0.017    0.020   0.379
  rs9898218       COPZ2          17:46106634      T    G     0.040    0.017   0.017
  rs7216504       COPZ2          17:46117341      A    G     0.016    0.019   0.421
  rs11650615      COPZ2/NFE2L1   17:46123698      G    C     0.019    0.017   0.289

^a^rs2298104. ^b^rs34192202. EA, effect allele; NEA, noneffect allele; β, overall estimated effect size for the effect allele; SE, overall standard error for effect size estimate; Chr, chromosome; pos, position.

Gene-Based Test {#s3_2}
---------------

Using the gene-based test, our results further showed no significant association between these COPI genes and AD susceptibility (significance level 0.05), including *COPA* (*P* = 0.3186 and 0.342), *COPB1* (*P* = 0.6095 and 0.212), *COPD/PHLDB1* (*P* = 0.2942 and 0.325), *COPZ1* (*P* = 0.3803 and 0.454), and *COPZ2* (*P* = 0.08175 and 0.177) using PLINK and VEGAS, respectively.

eQTLs Analysis {#s3_3}
--------------

As provided in [**Table 1**](#T1){ref-type="table"}, rs9898218 is the only SNP associated with AD risk with *P* = 0.017. We first evaluated the association between rs9898218 and *COPZ2* expression using the Braineac dataset. The results showed that rs9898218 G allele was associated with increased *COPZ2* expression in cerebellar cortex (*P* = 1.84E−02), but not in other nine brain tissues ([**Table 2**](#T2){ref-type="table"}).

###### 

Association between rs9898218 and *COPZ2* expression in Braineac dataset.

  SNP         EA   NEA   β        SE      *P* value      Tissue
  ----------- ---- ----- -------- ------- -------------- ---------------------------
  rs9898218   G    T     0.069    0.029   **1.84E−02**   Cerebellar cortex
  rs9898218   G    T     −0.012   0.031   6.94E−01       Frontal cortex
  rs9898218   G    T     0.029    0.027   2.79E−01       Hippocampus
  rs9898218   G    T     0.003    0.038   9.41E−01       Medulla
  rs9898218   G    T     0.028    0.032   3.81E−01       Occipital cortex
  rs9898218   G    T     −0.053   0.033   1.14E−01       Putamen
  rs9898218   G    T     −0.056   0.032   8.45E−02       Substantia nigra
  rs9898218   G    T     0.007    0.033   8.27E−01       Temporal cortex
  rs9898218   G    T     0.025    0.031   4.30E−01       Thalamus
  rs9898218   G    T     0.024    0.026   3.57E−01       Intralobular white matter

EA, effect allele; NEA, noneffect allele; β, overall estimated effect size for the effect allele; SE, overall standard error for effect size estimate. The significance level is P \< 0.05.

In cerebellar cortex, rs2298104 and rs7531886 were associated with the expression of *COPA*, and the rs11650615 was associated with the expression of *COPZ2*. In occipital cortex, both rs12033011 and rs7531886 were associated with the expression of *COPA*. In putamen, rs12033011, rs2298104, and rs7531886 were associated with the expression of *COPA* ([**Table 3**](#T3){ref-type="table"}).

###### 

P values for the association between other variants excluding rs9898218 and COPI gene expression in the Braineac dataset.

  SNP          Gene            Probe ID   CRBL    FCTX    HIPP   MEDU    OCTX    PUTM     SNIG   TCTX   THAL   WHMT
  ------------ --------------- ---------- ------- ------- ------ ------- ------- -------- ------ ------ ------ ------
  rs12033011   COPA            t2440143   0.23    0.055   0.37   0.096   0.017   0.03     0.23   0.66   0.14   0.43
  rs2298104    COPA            t2440143   0.021   0.24    0.31   0.26    0.065   0.006    0.81   0.68   0.4    0.51
  rs7531886    COPA            t2440143   0.021   0.23    0.31   0.17    0.025   0.0036   0.89   0.41   0.28   0.54
  rs61614746   COPZ1,MIR148B   t3416522   0.44    0.069   0.74   0.69    0.17    0.56     0.41   0.37   0.51   0.71
  rs11650615   COPZ2,MIR152    t3761054   0.005   0.93    0.31   0.65    0.47    0.18     0.18   0.93   0.29   0.26
  rs757352     COPZ2,MIR152    t3761054   0.1     0.82    0.43   0.44    0.45    0.28     0.32   0.33   0.45   0.36
  rs7216504    COPZ2,MIR152    t3761054   0.053   0.8     0.71   0.4     0.51    0.72     0.23   0.64   0.56   0.67

CRBL, cerebellar cortex; FCTX, frontal cortex; HIPP, hippocampus; MEDU, medulla; OCTX, occipital cortex; PUTM, putamen; SNIG, substantia nigra; TCTX, temporal cortex; THAL, thalamus; WHMT, intralobular white matter.

In two AD eQTLs datasets, 3 (rs11650615, rs9898218, and rs498872) of these 12 genetic variants are available. However, none of these three genetic variants was associated with the COPI gene expression in AD cerebellar and temporal cortex tissues ([**Table 4**](#T4){ref-type="table"}).

###### 

Association between COPI genetic variants and gene expression in AD brain tissues.

  SNP          EA   β        *P* value   PROBE          Gene     Tissue
  ------------ ---- -------- ----------- -------------- -------- --------------------
  rs11650615   G    −0.049   0.168       ILMN_1667361   COPZ2    AD cerebellar
  rs9898218    T    0.009    0.787       ILMN_1667361   COPZ2    AD cerebellar
  rs11650615   G    −0.017   0.701       ILMN_1667361   COPZ2    AD temporal cortex
  rs9898218    T    −0.008   0.850       ILMN_1667361   COPZ2    AD temporal cortex
  rs9898218    T    −0.005   0.787       ILMN_1739450   NFE2L1   AD cerebellar
  rs11650615   G    −0.004   0.851       ILMN_1739450   NFE2L1   AD cerebellar
  rs11650615   G    −0.019   0.389       ILMN_1739450   NFE2L1   AD temporal cortex
  rs9898218    T    −0.014   0.510       ILMN_1739450   NFE2L1   AD temporal cortex
  rs498872     A    0.033    0.264       ILMN_1666819   PHLDB1   AD cerebellar
  rs498872     A    −0.068   0.068       ILMN_1666819   PHLDB1   AD temporal cortex

EA, effect allele; NEA, noneffect allele; β, overall estimated effect size for the effect allele.

In whole blood, the eQTLs analysis showed that 11 of these 12 genetic variants could significantly regulate the expression of COPI genes including *COPA*, *COPB1*, *COPZ1*, *COPZ2*, *IFT46*, *NFE2L1*, and *PHLDB1* ([**Table 5**](#T5){ref-type="table"}).

###### 

Association between COPI genetic variants and gene expression in whole blood.

  SNP          Study     Tissue        Gene     Ensemble ID       *P* value   Sample
  ------------ --------- ------------- -------- ----------------- ----------- --------
  rs7531886    eQTLGen   Whole blood   COPA     ENSG00000122218   2.18E−109   30424
  rs12033011   eQTLGen   Whole blood   COPA     ENSG00000122218   4.07E−63    31675
  rs72868007   eQTLGen   Whole blood   COPB1    ENSG00000129083   1.03E−34    29143
  rs61614746   eQTLGen   Whole blood   COPZ1    ENSG00000111481   2.33E−34    31568
  rs757352     eQTLGen   Whole blood   COPZ2    ENSG00000005243   2.42E−04    31680
  rs9898218    eQTLGen   Whole blood   COPZ2    ENSG00000005243   1.47E−12    31684
  rs7216504    eQTLGen   Whole blood   COPZ2    ENSG00000005243   1.06E−14    27737
  rs11650615   eQTLGen   Whole blood   COPZ2    ENSG00000005243   6.53E−36    31562
  rs73022058   eQTLGen   Whole blood   IFT46    ENSG00000118096   1.60E−77    28802
  rs3132828    eQTLGen   Whole blood   IFT46    ENSG00000118096   8.78E−07    26557
  rs757352     eQTLGen   Whole blood   NFE2L1   ENSG00000082641   8.12E−55    14259
  rs7216504    eQTLGen   Whole blood   NFE2L1   ENSG00000082641   1.70E−07    10431
  rs11650615   eQTLGen   Whole blood   NFE2L1   ENSG00000082641   2.83E−12    14256
  rs73022058   eQTLGen   Whole blood   PHLDB1   ENSG00000019144   5.74E−04    28802
  rs498872     eQTLGen   Whole blood   PHLDB1   ENSG00000019144   1.12E−04    31300

Discussion {#s4}
==========

In recent years, COPI genes have been reported to be potentially involved in AD ([@B30]). For example, a cluster analysis of microarray data indicated the association between *COPA* and AD ([@B6]). Dynamic regulatory network reconstruction analysis showed gradually depressed activity of *COPA* ([@B13]). [@B1] highlighted 12 SNPs including rs7531886, rs12033011, rs72868007, rs73022058, rs3132828, rs498872, rs34280607, rs61614746, rs757352, rs9898218, rs7216504, and rs11650615 in COPI genes *COPA*, *COPB1*, *COPD/IFT46*, *COPD/PHLDB1*, *COPZ1*, *COPZ2*, and *COPZ2/NFE2L1* to be significantly associated with increased AD risk.

With the wide application of GWAS method in AD, it is possible and rapid to validate a finding using large-scale AD GWAS dataset. Here, we selected a large-scale AD GWAS dataset and performed both SNP and gene-based tests. We think that this large-scale dataset may be more powerful than the original dataset ([@B1]). Using SNP-based test, the results showed that rs9898218 T allele could increase AD risk with β = 0.040 and *P* = 0.017. Two gene-based test methods indicated no significant association between these COPI genes and AD susceptibility. Interestingly, eQTLs analysis further showed that rs9898218 T allele could reduce *COPZ2* expression in cerebellar cortex with β = −0.069 and *P* = 1.84E−02, but not in other nine brain tissues. Meanwhile, we identified other four genetic variants (rs12033011, rs2298104, rs7531886, and rs11650615) regulating the COPI gene expression in other human brain tissues. Importantly, the eQTLs analysis in whole blood further indicated that 11 of these 12 genetic variants could significantly regulate the expression of COPI genes.

*COPZ2* encodes a member of the adaptor complexes small subunit family ([@B44]). Evidence showed down-regulated *COPZ2* expression in most tumor cell lines and in individuals with kinds of cancer types ([@B44]). Interestingly, recent studies have highlighted the role of *COPZ2* in AD ([@B4]; [@B49]). [@B49] evaluated the effect of 6 months of tocotrienol rich fraction supplementation on gene expression in the hippocampus of wild-type group (n  =  4) and APPswe/PS1dE9 double transgenic AD mice (n   =  4). They found that Copz2 was significantly down-regulated in AD group compared with the WT group (*P* = 6.44E−05 and fold change = −4.5788) ([@B49]). [@B4] conducted a meta-analysis of gene expression data from about 1,600 human central nervous system tissues to investigate the transcriptional changes upon aging and as a result of AD. They found that *COPZ2* was up-regulated in AD (*P* = 3.90E−05 and fold change = 1.13).

In summary, these findings may provide important information about the association between COPI genes and AD susceptibility. Meanwhile, future studies are required to replicate these findings using large-scale GWAS and eQTLs datasets.
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